BAC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Bank of America Corp (BAC) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown strong financial performance and analysts maintain a generally positive outlook, the technical indicators suggest a bearish trend, and insider selling activity has significantly increased. Additionally, there are no strong proprietary trading signals or recent congress trading data to support a buy decision. Holding the stock or waiting for a better entry point might be more prudent.
The MACD histogram is positive and expanding, indicating potential bullish momentum. However, the RSI is neutral at 54.942, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 47.565, with resistance at 48.709 and support at 46.421. Overall, the technical indicators lean bearish.
Strong financial performance in Q4 2025, with revenue up 6.41% YoY, net income up 15.38% YoY, and EPS up 18.75% YoY.
Analysts maintain a generally positive outlook with multiple Buy ratings and price targets ranging from $50 to $
Positive sentiment from Jefferies and Goldman Sachs regarding net interest income growth and operating leverage.
Insider selling has increased by 508.86% over the last month, signaling potential lack of confidence from within the company.
Bearish moving averages and a lack of strong technical buy signals.
Broader market sentiment is negative, with the S&P 500 down 1.79%.
No recent congress trading data or influential figure activity to support a buy decision.
In Q4 2025, Bank of America reported strong growth: Revenue increased by 6.41% YoY to $26.09 billion, net income rose by 15.38% YoY to $7.2 billion, and EPS grew by 18.75% YoY to $0.95. This demonstrates solid operational performance and profitability.
Analysts maintain a generally positive outlook on BAC with multiple Buy ratings. Recent price target adjustments include Truist lowering its target to $57 from $60, Jefferies initiating coverage with a $60 target, and Goldman Sachs lowering its target to $57 from $67. Wolfe Research downgraded BAC to Peer Perform, citing valuation concerns and risks to forward estimates.
